GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries

Goldfinch Bio Initiates Phase 2 Clinical Trial Evaluating Novel Drug Candidate Gfb-887 As A Precision Medicine For Patients With Kidney Diseases

Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor

Voyager Therapeutics Announces Upcoming Presentations At The International Parkinson And Movement Disorder Society Virtual Congress 2020

Magenta Therapeutics Appoints Lisa M. Olson As Chief Scientific Officer And Kevin B. Johnson As Senior Vice President, Head Of Regulatory And Quality; Announces Transition Of Jason Ryan, Chief Operating And Financial Officer

Magenta Therapeutics Named Co-recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV

Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development

Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Magenta Therapeutics Announced It Will Present Clinical And Pre-Clinical Data From Across Immune And Blood System Reset Portfolio At European Society For Blood And Marrow Transplantation (EBMT) Annual Meeting

bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data, at the 46th Annual Meeting of the EBMT

MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Pliant Therapeutics Presents Data at The Digital International Liver Congress™ 2020

Relay Therapeutics Reports Second Quarter 2020 Financial Results

FDA Approves Foundation Medicine's FoundationOne®Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer

Editas Medicine Receives Rare Pediatric Disease Designation For EDIT-301 For The Treatment Of Sickle Cell Disease

Sage Therapeutics to Host Sage FutureCast Webcast

Tango Therapeutics Announces $50 Million Equity Financing

OneOncology and Foundation Medicine Unveil First-of-its-Kind Partnership to Advance Personalized Medicine at Community Oncology Practices

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting

Gilead Sciences And Tango Therapeutics To Expand Strategic Oncology Collaboration

Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)

bluebird bio Appoints Denice Torres to Board of Directors

MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results

Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020

Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

Sesen Bio Reports Second Quarter 2020 Financial Results and Business Update

Sage Therapeutics Announces Second Quarter 2020 Financial Results and Highlights Pipeline and Business Progress

Voyager Therapeutics Announces Second Quarter 2020 Financial Results And Corporate Updates

Jounce Therapeutics Reports Second Quarter 2020 Financial Results

CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

Editas Medicine Announces Second Quarter 2020 Results And Update

Editas Medicine Regains Full Global Rights To Ocular Medicines

Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results

Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Allena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update

bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress

Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8:00 a.m. ET

GBT Reports Recent Business Progress and Second Quarter 2020 Financial Results

MyoKardia Reports Second Quarter 2020 Financial Results

MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results

Voyager Therapeutics To Report Second Quarter 2020 Financial Results And Participate In Upcoming Investor Conferences

Voyager Therapeutics Provides Update On AbbVie Vectorized Antibody Collaborations

Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China

Blueprint Medicines Reports Second Quarter 2020 Financial Results

Agios Reports Business Highlights and Second Quarter 2020 Financial Resultsa